F2G

83 employees

F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.

Basic info

Industry

biotechnology research

Sectors

Biotechnology

Health Care

Genetics

Medical

Pharmaceutical

Date founded

1998

Funding rounds raised

Total raised

$70M

from 22 investors over 22 rounds

F2G raised $70M on August 4, 2022

Investors: Forbion and Sofinnova Partners

F2G raised $61M on August 12, 2020

Investors: Brace Pharma Capital, Morningside Venture Capital 晨兴资本 and Advent Life Sciences

F2G raised $27M on November 22, 2018

Investors: European Investment Bank

F2G raised $60M on June 20, 2016

Investors: Sectoral Asset Management, Brace Pharma Capital, Sunstone Life Science Ventures, Aisling Capital, Merifin Capital, Novo Holdings and Advent Life Sciences

F2G raised $2.3M on September 19, 2014

Investors: Innovate UK

F2G raised $30M on September 5, 2012

Investors: FraserFinance, Advent Venture Partners, Merifin Capital, Sunstone Life Science Ventures and Astellas Venture Capital L.L.C.

F2G raised $12M on August 18, 2008

Investors: Astellas Venture Capital L.L.C. and Merifin Capital

F2G raised $8.7M on March 22, 2006

Investors: Astellas Venture Capital L.L.C.

F2G